{"id":"NCT05857163","sponsor":"TenNor Therapeutics (Suzhou) Limited","briefTitle":"Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection","officialTitle":"Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Rifasutenizol (TNP 2198) in Combination With Rabeprazole and Amoxicillin in the Primary Treatment of Participants With H. Pylori Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-05-18","primaryCompletion":"2023-12-24","completion":"2024-03-26","firstPosted":"2023-05-12","resultsPosted":"2025-08-17","lastUpdate":"2025-08-17"},"enrollment":700,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["H.Pylori Infection"],"interventions":[{"type":"DRUG","name":"Rifasutenizol capsules","otherNames":["TNP-2198 capsules"]},{"type":"DRUG","name":"Rabeprazole sodium enteric-coated tablets","otherNames":["Rabeprazole"]},{"type":"DRUG","name":"Amoxicillin Capsules","otherNames":["Amoxicillin"]},{"type":"DRUG","name":"Clarithromycin placebo tablets","otherNames":["Clarithromycin placebo"]},{"type":"DRUG","name":"Bismuth potassium citrate placebo capsules","otherNames":["Bismuth placebo"]},{"type":"DRUG","name":"Clarithromycin tablets","otherNames":["Clarithromycin"]},{"type":"DRUG","name":"Bismuth potassium citrate capsules","otherNames":["Bismuth"]},{"type":"DRUG","name":"Rifasutenizol placebo capsules","otherNames":["Rifasutenizol placebo"]}],"arms":[{"label":"Test Group","type":"EXPERIMENTAL"},{"label":"Control Group","type":"ACTIVE_COMPARATOR"}],"summary":"A multi-center, randomized, double-blind, bismuth-containing quadruple active comparator-controlled Phase 3 clinical study to evaluate the efficacy and safety of Rifasutenizol in combination with rabeprazole and amoxicillin in the primary treatment of participants with H. pylori infection using an adaptive design with sample size re-estimation.","primaryOutcome":{"measure":"Eradication Rate of H.Pylori Infection","timeFrame":"4 to 6 weeks after the last dose of the study drugs","effectByArm":[{"arm":"Test Group","deltaMin":323,"sd":null},{"arm":"Control Group","deltaMin":304,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":22},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":351},"commonTop":["Dysgeusia","Diarrhoea","Nausea","Dizziness"]}}